Literature DB >> 12902502

Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.

Travis C McGuire1, Steven R Leib, Robert H Mealey, Darrilyn G Fraser, David J Prieur.   

Abstract

Control of a naturally occurring lentivirus, equine infectious anemia virus (EIAV), occurs in most infected horses and involves MHC class I-restricted, virus-specific CTL. Two minimal 12-aa epitopes, Env-RW12 and Gag-GW12, were evaluated for presentation by target cells from horses with an equine lymphocyte Ag-A1 (ELA-A1) haplotype. Fifteen of 15 presented Env-RW12 to CTL, whereas 11 of 15 presented Gag-GW12. To determine whether these epitopes were presented by different molecules, MHC class I genes were identified in cDNA clones from Arabian horse A2152, which presented both epitopes. This horse was selected because it is heterozygous for the SCID trait and is used to breed heterozygous females. Offspring with SCID are used as recipients for CTL adoptive transfer, and normal offspring are used for CTL induction. Four classical and three putative nonclassical full-length MHC class I genes were found. Human 721.221 cells transduced with retroviral vectors expressing each gene had equine MHC class I on their surface. Following peptide pulsing, only cells expressing classical MHC class I molecule 7-6 presented Env-RW12 and Gag-GW12 to CTL. Unlabeled peptide inhibition of (125)I-labeled Env-RW12 binding to 7-6-transduced cells demonstrated that Env-RW12 affinity was 15-fold higher than Gag-GW12 affinity. Inhibition with truncated Env-RW12 demonstrated that amino acid positions 1 and 12 were necessary for binding, and single substitutions identified positions 2 and 3 as possible primary anchor residues. Since MHC class I 7-6 presented both epitopes, outbred horses with this allele can be immunized with these epitopes to optimize CTL responses and evaluate their effectiveness against lentiviral challenge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902502     DOI: 10.4049/jimmunol.171.4.1984

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Authors:  Darrilyn G Fraser; Steve R Leib; Bao Shan Zhang; Robert H Mealey; Wendy C Brown; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Authors:  Tobias Bergmann; Carrie Moore; John Sidney; Donald Miller; Rebecca Tallmadge; Rebecca M Harman; Carla Oseroff; Amanda Wriston; Jeffrey Shabanowitz; Donald F Hunt; Nikolaus Osterrieder; Bjoern Peters; Douglas F Antczak; Alessandro Sette
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

3.  Development of a DNA microarray for detection of expressed equine classical MHC class I sequences in a defined population.

Authors:  Joshua D Ramsay; Steven R Leib; Lisa Orfe; Douglas R Call; Rebecca L Tallmadge; Darrilyn G Fraser; Robert H Mealey
Journal:  Immunogenetics       Date:  2010-08-04       Impact factor: 2.846

4.  Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.

Authors:  Robert H Mealey; Amin Sharif; Shirley A Ellis; Matt H Littke; Steven R Leib; Travis C McGuire
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

5.  Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-04-08       Impact factor: 2.046

6.  Analysis of MHC class I genes across horse MHC haplotypes.

Authors:  Rebecca L Tallmadge; Julie A Campbell; Donald C Miller; Douglas F Antczak
Journal:  Immunogenetics       Date:  2010-01-23       Impact factor: 2.846

7.  Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-07-25       Impact factor: 2.046

8.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

9.  Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.

Authors:  Robert H Mealey; Steven R Leib; Sarah L Pownder; Travis C McGuire
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

Authors:  Robert H Mealey; Steven R Leib; Matt H Littke; Bettina Wagner; David W Horohov; Travis C McGuire
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.